A double‐blind study on ulotaront's impact on weight‐related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70110 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Snezana Milanovic und 11 weiteren Autor:innen. Beteiligte Einrichtung: Sumitomo Pharma America, Inc., Marlborough, Massachusetts, USA. Hauptthemen laut MEDLINE: Schizophrenia, Prediabetic State, Metabolic Syndrome, Antipsychotic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
Antipsychotics increase metabolic syndrome ( MetSyn ) and diabetes risk. Preclinical and translational research data suggest that ulotaront, an investigational trace amine‐associated receptor 1 (TAAR1) agonist, may have beneficial metabolic effects. This Phase 1b study collected pilot data on 4‐week ulotaront exposure and weight‐associated metabolic markers. Materials and Methods A double‐blind, randomised, multiple‐dose within subject trial compared ulotaront to continued prior antipsychotic ( PA ) on metabolic markers in schizophrenia patients at high diabetes risk (presence of MetSyn and prediabetes). Metabolic characteristics of patients at check‐in were compared to a matched historical cohort without schizophrenia or antipsychotic exposure.
Results
When compared to PA , ulotaront treatment showed improvement trends for high glucose clamp, low glucose clamp, liver fat, liver fibro‐inflammation, back muscle fat infiltration, pancreas fat and pancreas volume. Visceral adipose tissue and weight changes favoured ulotaront treatment ( p < 0.001, p = 0.047). Liver fibro‐inflammation distinguished antipsychotic‐induced metabolic changes from the historical cohort ( p = 0.002).
Conclusions
Despite the sample size constraints due to early study termination, all key endpoint trends and statistically significant differences favoured ulotaront over previous antipsychotics, lending support that ulotaront may improve antipsychotic‐induced weight‐associated markers. Liver fibro‐inflammation may serve as a potential marker for antipsychotic‐induced MetSyn and prediabetes, and possible treatment target. Further research is needed to build on these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sumitomo Pharma America, Inc., Marlborough, Massachusetts, USA.
- Carmot Therapeutics, Berkley, California, USA.
- Evolution Research Group, Edison, New Jersey, USA.
- University of Jamestown, Jamestown, North Dakota, USA.
- Perspectum Ltd., Oxford, UK.
ORCID-Profile: Snezana Milanovic
Zitieren
APA
Milanovic, S., Lew, R., Xiong, K., Casavant, E., Galluppi, G., Chen, Y. L., Lai, Y., Chakravarthy, M., Dehn, C., Jackson, E., Koblan, K., & Hopkins, S. C. (2026). A double‐blind study on ulotaront's impact on weight‐related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70110
Vancouver
Milanovic S, Lew R, Xiong K, Casavant E, Galluppi G, Chen YL, et al. A double‐blind study on ulotaront's impact on weight‐related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70110
BibTeX
@article{Milanovic2026,
author = {Milanovic, Snezana and Lew, Robert and Xiong, Kuangnan and Casavant, Emily and Galluppi, Gerard and Chen, Yu-Luan and Lai, Yongquan and Chakravarthy, Manu and Dehn, Clay and Jackson, Edward and Koblan, Kenneth and Hopkins, Seth C},
title = {A double‐blind study on ulotaront's impact on weight‐related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70110}
}
EUVIMED